Tianjin Xinglian Peptide Biotechnology
ConjuStar focuses on developing next generation innovative oncology therapies.
Launch date
Employees
Market cap
-
Enterprise valuation
$50—74m (Dealroom.co estimates Jan 2024.)
Shanghai Shanghai (HQ)
Authorizing premium user...